The drug levosimendan did not improve survival for patients with decompensated heart failure when compared with a more widely-used treatment for this condition, dobutamine, according to a study in the JAMA.Acute decompensated heart failure (ADHF; severe heart failure characterized by inability of the heart to maintain adequate blood circulation) remains a common cause of hospitalization worldwide, but appropriate treatment is not always clear. [click link for full article]